ArticleAdvanced therapeutics2019
Targeting of Nanotherapeutics to Infection Sites for Antimicrobial Therapy.
Article in Advanced therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Surface Plasmon Resonance-Based Biodetection Systems: Principles, Progress and Applications-A Comprehensive Review.Biosensors · 2025Review
- Antimicrobial Polymer Surfaces Containing Quaternary Ammonium Centers (QACs): Synthesis and Mechanism of Action.International journal of molecular sciences · 2024Review
- Lung Inflammation Resolution by RvD1 and RvD2 in a Receptor-Dependent Manner.Pharmaceutics · 2023Article
- Remote Co-loading of amphipathic acid drugs in neutrophil nanovesicles infilled with cholesterol mitigates lung bacterial infection and inflammation.Biomaterials · 2023Article
- Electrosprayed Nanoparticles Containing Hydroalcoholic Extract ofAdvanced pharmaceutical bulletin · 2023Article
- Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer.Advanced drug delivery reviews · 2022Review
- Surface Design for Antibacterial Materials: From Fundamentals to Advanced Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design.Acta pharmaceutica Sinica. B · 2021Review
- Human neutrophil membrane-derived nanovesicles as a drug delivery platform for improved therapy of infectious diseases.Acta biomaterialia · 2021Article
- Nanomedicines for the Efficient Treatment of Intracellular Bacteria: The "ART" Principle.Frontiers in chemistry · 2021Review
- Co-delivery of resolvin D1 and antibiotics with nanovesicles to lungs resolves inflammation and clears bacteria in mice.Communications biology · 2020Article
- Boron doped silver-copper alloy nanoparticle targeting intracellular S. aureus in bone cells.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Bacterial infections cause a wide range of host immune disorders, resulting in local and systemic tissue damage. Antibiotics are pharmacological interventions for treating bacterial infections, but increased antimicrobial resistance and the delayed development of new antibiotics have led to a major global health threat, the so-called "superbugs". Bacterial infections consist of two processes: pathogen invasion and host immune responses. Developing nanotherapeutics to target these two pathways may be effective for eliminating bacteria and restoring host homeostasis, thus possibly finding new treatments for bacterial infections. This review offers new approaches for developing nanotherapeutics based on the pathogenesis of infectious diseases. We have discussed how nanoparticles target infectious microenvironments (IMEs) and how they target phagocytes to deliver antibiotics to eliminate intracellular pathogens. We also review a new concept-host-directed therapy for bacterial infections, such as targeting immune cells for the delivery of anti-inflammatory agents and vaccine developments using bacterial membrane-derived nanovesicles. This review demonstrates the translational potential of nanomedicine for improving infectious disease treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.